Drug updated on 3/28/2024
Dosage Form | Injection (intravenous; 17.5 mg/5 mL) |
Drug Class | GD2-binding monoclonal antibodies |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Unituxin (dinutuximab) Prescribing Information. | 2020 | FDA |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Clinical and pharmacoeconomic combined report: dinutuximab (Unituxin) for neuroblastoma. | 2021 | CADTH |
Commonly reported adverse events associated with pediatric immunotherapy: a systematic review from the Children’s Oncology Group. | 2021 | Journal of Pediatric Oncology Nursing |
Anti-GD2 antibody-containing immunotherapy postconsolidation therapy for people with high-risk neuroblastoma treated with autologous haematopoietic stem cell transplantation. | 2019 | Cochrane Database of Systematic Reviews |
Final clinical guidance report: dinutuximab (Unituxin) for neuroblastoma. | 2019 | CADTH |